Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afatinib + vinorelbine
- Development stage
- Phase 3
- Lead developer
- Boehringer Ingelheim
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Afatinib (BIBW 2992) is an oral, irreversible inhibitor of the ErbB family of tyrosine kinases, including epidermal growth factor receptor (EGFR/ErbB1), HER2 (ErbB2), and to a lesser extent HER4 (ErbB4). It blocks signaling pathways involved in the proliferation and survival of cancer cells. Vinorelbine is a semi-synthetic vinca alkaloid that inhibits microtubule assembly, thereby disrupting mitosis and leading to cell death. The combination has been investigated for use in advanced solid tumors, particularly HER2-overexpressing breast cancer and non-small cell lung cancer. Afatinib was developed by Boehringer Ingelheim[1][4][5][6][8].
- Other names
- afatinib + vinorelbine
02
Targets
EGFR (Epidermal growth factor receptor)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)TUBA (Tubulin alpha/beta dimer)
Beyond the preview
Go deeper on afatinib + vinorelbine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afatinib + vinorelbine.